Sacramento, CA Clinical Trials Report — July 2026

Sacramento participants should act quickly if they match a study nearing enrollment: 34 recruiting trials are expected to close within the next 90 days, including 5 that accept healthy volunteers. Across the city, 567 trials are recruiting at 212 research facilities, giving patients and volunteers a broad range of local options.

Closing windows across several conditions

Enrollment can end before a projected closing date if a study reaches its participant target. The conditions most represented among Sacramento trials closing soon are:

• Atopic dermatitis (2 trials)
• Heart failure (2 trials)
• Scarring (2 trials)
• Asthma (1 trial)
• Breast cancer screening (1 trial)
• Breast carcinoma in situ (1 trial)
• Breast cancer (1 trial)
• Clinical high risk for psychosis (1 trial)
• Colorectal polyp (1 trial)
• De Quervain tenosynovitis (1 trial)

People with one of these conditions should contact the relevant study site soon to confirm whether local enrollment remains open. The dataset identifies 5 closing-soon trials that accept healthy volunteers, but does not provide the number of remaining places in each study.

July’s new study activity

Sacramento opened 8 new trials in July, down from 12 in May. The six-month pattern has been uneven: 13 opened in February, 10 in March, 5 in April, 12 in May, 12 in June, and 8 in July. The August figure in the trend data is 1.

New studies cover aging, anxiety, atrial fibrillation, breast cancer, cardiovascular diseases, caregiver burden, chronic kidney disease, depression, energy expenditure, and aging mid-face. By study type, July’s openings include 2 device trials, 2 drug trials, and one each classified as behavioral, biological, other, and procedure.

One notable new opportunity is a Phase 2 drug study sponsored by Yarrow Bioscience, Inc.:

• NCT07682896, “Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease,” plans to enroll 232 participants. The study evaluates YB-101’s effect on thyroid function, safety and tolerability, and how the drug is distributed through the body. It includes a blinded treatment period followed by a double-blinded treatment period.

Other July sponsors include University of California, Davis, which sponsors 3 new trials, as well as EchoPixel, Inc., EicOsis Human Health Inc., Lynch Regenerative Medicine, Nisha Acharya, and Yarrow Bioscience, Inc. The new-study mix includes 4 trials categorized as other, 3 industry-sponsored studies, and 1 network study.

Where Sacramento has the most research activity

The University of California Davis system is the city’s strongest center of trial activity, particularly for cancer research. UC Davis-affiliated locations appear repeatedly among the leading facilities, while Mercy, Sutter, Kaiser Permanente, and South Sacramento cancer centers provide additional access points for oncology and other specialties.

• University of California Davis Comprehensive Cancer Center (100 trials)
• Mercy Cancer Center - Sacramento (41 trials)
• Sutter Medical Center Sacramento (37 trials)
• Kaiser Permanente-South Sacramento (34 trials)
• Kaiser Permanente Downtown Commons (33 trials)
• UC Davis Medical Center (30 trials)
• University of California, Davis (29 trials)
• UC Davis Health (20 trials)
• University of California Davis (20 trials)
• South Sacramento Cancer Center (15 trials)
• UC Davis (15 trials)
• Research Site (14 trials)

For people seeking cancer studies, the University of California Davis Comprehensive Cancer Center is the clearest first place to search, with Mercy Cancer Center - Sacramento, Sutter Medical Center Sacramento, and South Sacramento Cancer Center also offering substantial local activity. Kaiser Permanente’s South Sacramento and Downtown Commons locations broaden access for eligible members and other patients, depending on the individual study.

Healthy volunteers and eligibility

Only 1 of July’s 8 new trials accepts healthy volunteers. Even so, 44 healthy-volunteer trials are recruiting in Sacramento overall, so people without a diagnosed condition still have local opportunities beyond the month’s new openings.

Eligibility information shows that 1 July trial includes children and 8 include older adults. No new trial is limited to female participants, and no new trial is limited to male participants. Screening requirements vary and may include age, health history, current medications, prior treatment, travel, and study-specific testing.

Other California cities to consider

Participants willing to travel can also search nearby California research markets. Recruiting trials are listed in Los Angeles (25), San Francisco (22), San Diego (16), Palo Alto and Duarte (10 each), La Jolla (8), and Anaheim and Stanford (7 each).

With closing dates approaching for dozens of Sacramento studies, patients who match an affected condition and healthy volunteers seeking one of the available openings should review eligibility and contact study teams now. The city’s large UC Davis research network and continuing stream of new studies provide a strong foundation for additional opportunities as the second half of 2026 develops.